107
Views
7
CrossRef citations to date
0
Altmetric
Original Articles: Research

Enhancement of lytic activity of leukemic cells by CD8+ cytotoxic T lymphocytes generated against a WT1 peptide analogue

, , , , , , , , , , & show all
Pages 260-269 | Received 19 Jul 2008, Accepted 22 Oct 2008, Published online: 01 Jul 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Nadine Nelson, Marta Lopez-Pelaez, Asis Palazon, Edmund Poon, Maike De La Roche, Simon Barry, Viia Valge-Archer, Robert W. Wilkinson, Simon J. Dovedi & Paul D. Smith. (2019) A cell-engineered system to assess tumor cell sensitivity to CD8+ T cell-mediated cytotoxicity. OncoImmunology 8:8, pages 1-10.
Read now
Jeffrey M Clarke, Michael A Morse, H Kim Lyerly, Timothy Clay & Tayuka Osada. (2010) Adenovirus vaccine immunotherapy targeting WT1-expressing tumors. Expert Opinion on Biological Therapy 10:6, pages 875-883.
Read now
Justin Kline. (2009) Will changing the face of WT1 make it more attractive to T cells?. Leukemia & Lymphoma 50:2, pages 156-157.
Read now

Articles from other publishers (4)

Thi HO Nguyen, Amabel CL Tan, Sue D Xiang, Anne Goubier, Kim L Harland, E Bridie Clemens, Magdalena Plebanski & Katherine Kedzierska. (2017) Understanding CD8 + T-cell responses toward the native and alternate HLA-A∗02:01-restricted WT1 epitope . Clinical & Translational Immunology 6:3, pages e134.
Crossref
Hideho OkadaMichael E. Scheurer, Saumendra N. SarkarMelissa L. Bondy. (2013) Integration of epidemiology, immunobiology, and translational research for brain tumors. Annals of the New York Academy of Sciences 1284:1, pages 17-23.
Crossref
Jeffrey J. Molldrem. (2012) What T cells see in WT-1. Blood 120:8, pages 1540-1541.
Crossref
Ghofran Al Qudaihi, Cynthia Lehe, Anne Dickinson, Khaled Eltayeb, Walid Rasheed, Naeem Chaudhri, Mahmoud Aljurf & Said Dermime. (2010) Identification of a novel peptide derived from the M-phase phosphoprotein 11 (MPP11) leukemic antigen recognized by human CD8+ cytotoxic T lymphocytes. Hematology/Oncology and Stem Cell Therapy 3:1, pages 24-33.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.